SOURCE: ViroCyt, Inc.

September 29, 2015 08:30 ET

ViroCyt® Launches ViroTag® for Direct, Real-Time Antibody-Based Virus Quantification

BOULDER, CO--(Marketwired - September 29, 2015) - ViroCyt®, the leader in rapid virus quantification, announced today the introduction of a new paradigm in virus quantification building upon its award winning Virus Counter technology. The importance of viruses as both a health threat and as a tool for addressing a growing list of diseases continues to increase at a significant pace. Our ability to meet these challenges, however, has been limited by the lack of robust manufacturing technologies capable of supporting the rapid scale up of production. Most noteworthy has been the absence of real-time, inline analytical methods for the development and manufacture of products created either directly from viruses or indirectly using virus-based systems. This includes viral vaccines, protein expression systems, gene delivery vectors and oncolytic viruses.

In response to this unmet need, ViroCyt has developed a novel approach enabling direct, biologically-specific quantification of viruses in minutes rather than the days or weeks required by more traditional approaches. Marketed under the tradename ViroTag®, this new product category utilizes a fluorescently-labeled, high-affinity antibody targeted to the virus of interest. During a 1-minute sample analysis, the preparation is evaluated with the Virus Counter® 3100, an instrument developed expressly for the purpose of real-time virus quantification.

"Our customers have asked for virus specific quantification methods for use with the Virus Counter and we have responded with the development and release of the first two reagents designed specifically for baculovirus and adenovirus. We expect these new products to be the first in a line of virus-targeted reagents that will continue to expand the utility and reach of the Virus Counter technology," stated Robert Kline, President and CEO of ViroCyt.

Added Chris Kemp, President of Kempbio and a leading bioprocessing expert, "During beta testing, ViroTag provided fast, easy, dead-on virus counts regardless of the sample source. The simplicity, specificity and extended dynamic range takes virus particle counting to an exciting new level."

About ViroCyt, Inc.

ViroCyt, Inc. was created with the goal of bringing game-changing solutions to the Life Science industry. Our primary focus is replacing outdated technologies that slow down the pace of virus-related research and product development. Additional information can be found at

Contact Information

  • Contact Information
    Michael Artinger
    Vice President, Marketing & Strategic Partnering
    ViroCyt, Incorporated
    Email contact